Sarcopenia, characterised by an ongoing loss of skeletal muscle mass and reduced strength and function, is frequently observed in patients with non-small cell lung cancer (NSCLC). However, the relationship between sarcopenia and the prognosis of NSCLC treated with immune checkpoint inhibitors (ICIs) remains unclear. This aimed to assess whether sarcopenia is an independent prognostic factor for survival in patients with advanced NSCLC receiving ICIs. For this retrospective cohort study, we analysed the medical records of patients attending our hospital aged 18–75 years who were newly diagnosed with stage IIIB to stage IV NSCLC, and who had received ICIs as first- or second-line therapy between May 2019 and April 2022. The skeletal muscle index (SMI) was calculated from computed tomography (CT) images and relevant clinical characteristics within 4 weeks of initiating treatment and used to diagnose sarcopenia status. The Kaplan-Meier method and log-rank test were used to calculate and compare patients' progression-free survival (PFS). Cox proportional hazard regression was used to examine the associations between sarcopenia and survival outcomes. The chi-square test was used to compare treatment response outcomes, such as the objective response rate (ORR), disease control rate (DCR), and immunotherapy-related adverse events (irAEs), between individuals with and without sarcopenia. Additionally, the Student's t-test was utilised to compare SMI values between patients by their objective response (OR) and disease control (DC). Finally, the Mann-Whitney U test was used to compare nutritional and inflammatory indicators between the sarcopenia groups. The study enrolled 70 patients, of whom 34 (48.6%) were diagnosed with sarcopenia. The median PFS of patients with and without sarcopenia was 7.5 vs. 13.4 months, respectively (p = 0.006). The proportional hazards regression analysis showed sarcopenia to be an independent prognostic factor for shorter PFS (hazard ratio (HR): 0.504, 95% CI: 0.265–0.962, p = 0.038). Using chi square tests, we found significant differences in the ORR (20.59% vs. 58.33%, p = 0.001) and occurrence of any irAEs (44.1% vs. 22.2%, p = 0.028) between the sarcopenia and the non-sarcopenia groups, respectively. The Student's t-test showed a significant difference in SMI between the ORR group and the non-ORR group (49.99 ± 7.00 vs. 42.98 ± 2.18 cm2/m2, p = 0.0015). While the sarcopenia group were with significantly a lower CD4+/CD8+ ratios and a higher C-reactive protein (CRP) level (p = 0.026, p = 0.011, respectively). Conclusions: This study found that sarcopenia is a significant predictor of a poor prognosis for patients with advanced NSCLC receiving ICIs. Multiple inflammatory and immune functions related to prognosis also differ by sarcopenia status.
21 February 2025 in CNS Neuroscience & Therapeutics
Objective: Xiao‐Chai‐Hu‐Tang (XCHT) has been demonstrated to exert an antidepressant effect during long‐term clinical practices. However, the potential mechanisms of XCHT remain unknown. This study aims to investigate the effect of XCHT on chronic unpredictable mild stress‐induced mice with depressive‐like behaviors and to explore the underlying mechanisms. Methods: The active compositions and potential related targets of XCHT in the brain were obtained through UPLC‐Q‐TOF‐MS, network pharmacology, and bioinformatics analyses, verified by experimental validation. Then, the protein–protein interaction (PPI), Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, and molecular docking were used to predict the core targets and mechanisms of XCHT on depression. After being treated with XCHT standard decoction, based on enzyme‐linked immunosorbent assay (ELISA), non‐targeted metabolism, targeted LC–MS analyses, RNA‐seq, quantitative RT‐PCR, immunofluorescence, and western blotting were determined to clarify the mechanism of XCHT in the treatment of anxiety and depression disorder. Results: In total, 166 active ingredients and 525 related targets of XCHT were detected and selected from the network databases. The inflammatory response and metabolism of neurotransmitters were the main related signaling pathways predicted by KEGG enrichment analyses. Behavioral testing shows that XCHT has antidepressant effects, and untargeted metabolomic studies showed it significantly reduced levels of the neurotoxic substance quinoline acid. Combining the results of molecular docking, RNA‐seq, and western blot revealed that XCHT regulated nerve regeneration via BDNF/TrkB/CREB and PI3K/AKT signaling pathways. Immunofluorescence analysis revealed that XCHT downregulated the chronic stress‐induced activation of microglia and astrocytes in the hippocampus. Conclusion: XCHT exerts antidepressant functions by modulating neuroinflammation and neuroregeneration.
Immunotherapy combined with chemotherapy has emerged as the first-line standard treatment for advanced gastric cancer. However, obvious survival benefits in patients with peritoneal metastatic gastric cancer remain elusive. The combination of anti-angiogenic agents and immunotherapy has shown synergistic effects. However, currently there are no relevant reports on the efficacy and safety of immunotherapy combined with anti-angiogenic agents and chemotherapy in patients with gastric cancer peritoneal metastatic. We conducted a multicenter, retrospective clinical study in four independent healthcare facilities, enrolling advanced gastric cancer patients with peritoneal metastatic who received immunotherapy in combination with anti-angiogenic agents and chemotherapy between January 2020 and March 2023. All patients were treated with triple combination regimen for at least two and up to eight cycles before being adjusted for immunotherapy and targeted therapy. This study observed overall survival (OS) and time to treatment failure (TTF), as well as an exploratory analysis of the impact of ascites and peritoneal metastases on the prognosis of all patients. This study enrolled 30 eligible patients in the final analysis cohort. The median TTF and OS were 7.03 months [95% confidence interval (CI), 4.17–9.89] and 13.33 months (95% CI: 10.96–15.71), respectively. The 6-month and 12-month OS rates were 83.0% and 53.0%, respectively. The objective response rate (ORR) was 58.3%, and the disease control rate (DCR) was 83.3% in 12 patients who were evaluated for response with at least one measurable lesion. Exploratory subgroup analysis revealed that the median TTF and OS in the subgroup without ascites were significantly better than those in the subgroup with ascites, with a median TTF of 9.03 vs. 4.63 months (χ2 = 8.579, P = 0.003), and median OS of 17.83 vs. 11.87 months (χ2 = 6.155, P = 0.013). Conversely, the extent of peritoneal metastasis had little effect on TTF and OS. The common adverse reactions were leukopenia (46.67%), neutropenia (43.33%), fatigue (36.67%), anemia (36.67%), decreased appetite (36.67%), thrombocytopenia (33.33%), and hypertension (33.33%). No new safety signals were observed. The combination of immunotherapy, anti-angiogenic agents, and chemotherapy demonstrated therapeutic potential with a manageable safety profile in patients with peritoneal metastatic gastric cancer. These findings should be interpreted cautiously due to the inherent limitations of retrospective analyses and need to be validated through prospective randomized controlled trials to establish clinical efficacy and optimize patient selection criteria.
Reproductive factors significantly impact the incidence of breast cancer (BC), a concerning trend. This study aims to reassess this association and provide recommendations for fertility policies to delay the onset of BC. Utilizing data from a national survey, we applied weighted Cox and restricted cubic spline (RCS) methods to evaluate the impact of various modifiable and non-modifiable reproductive factors on breast cancer (BC) incidence. Interaction and subgroup analyses were conducted to investigate favorable fertility combinations and identify target populations. Our analysis included 15,938 cases, representing 63,247,160 women in the United States, with 4.06% diagnosed as BC survivors. Multiple models consistently demonstrated that a later age at menarche (AM), higher parities, and an earlier age at first birth (AFB) were associated with a delayed BC onset. Specifically, women with four or more parities experienced a 32% reduction in BC risk (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.48–0.95), while those with an AFB of 25 years or older faced a 51% increased risk (HR 1.51, 95% CI 1.17–1.94). Women with an AM of 13 years or older had a 26% decreased risk in multivariate Cox analysis. Restricted cubic spline (RCS) analysis revealed a negative linear relationship between parities and BC risk. However, interaction and subgroup analyses indicated that these factors were less impactful than an earlier AFB, particularly in the high-risk group, including individuals with early AM or long-term survivors, where no significant differences were observed. Among reproductive factors, both modifiable factors such as increased parity and earlier AFB, as well as the non-modifiable factor of later AM, delay the onset of BC. The effect of an earlier AFB in postponing BC onset are notably more pronounced compared to having more children, especially within specific high-risk cohorts.
The tyrosine kinase ephrin type-A receptor 2 (EPHA2) was remarkably elevated expressed in various tumors and plays a crucial role in cancer tumorigenesis and progression, while pan-cancer analyses are currently lacking. This study was designed to analyze the expression status and prognostic significance of EPHA2 in pan-cancer. By mining The Cancer Genome Atlas data, we performed a comprehensive and systematic characterization of EPHA2 across >10,000 samples of 33 types of cancer. EPHA2 expressions were substantially different in most of the normal control and tumor tissues, and it was considerably associated with the prognosis of tumor patients. EPHA2 gene modifications in malignant tumors were mainly missense mutations. There was a significant correlation between EPHA2 expression and cancer-associated fibroblasts in most The Cancer Genome Atlas cancers. Furthermore, functional enrichment analysis showed that the biological role of EPHA2 in tumors was mainly involved in some noticeably pro-oncogenic pathways, such as the Ras signaling pathway, PI3K-Akt signaling pathway, ErbB signaling pathway, MAPK signaling pathway, etc. This study provided the first pan-cancer analyses of EPHA2 in various tumors, and EPHA2 was potentially involved in many cancer types and can be developed as candidates for cancer diagnosis, prognosis, and therapeutic biomarkers. In addition, EPHA2 seemed to be a key modulator of the tumor immune microenvironment and might be a potential biomarker in predicting the immunotherapeutic efficacy for cancer patients.
Preterm birth, defined as delivery before 37 weeks of gestation, is a major cause of neonatal morbidity and mortality. DNA methylation changes at CpG sites have been associated with the risk of preterm birth. This study aimed to identify differential CpG sites in cord blood and develop predictive machine learning models based on these methylation changes to assess preterm birth risk. Methylome data from 110 neonatal cord blood samples in the GSE110828 dataset were analyzed to identify CpG sites differing between preterm and full-term births (88 for training, and 22 for testing, respectively). Key CpG sites were selected using Lasso, Elastic Net, and Random Forest. Forty-five predictive models were constructed and evaluated for accuracy, precision, recall, and F1 score. Sixty-six CpG sites showed significant differences between preterm and full-term groups. Four models, including Random Forest with Lasso and Gradient Boosting with Random Forest, achieved optimal predictive performance, each with a validation accuracy of 93.75%. DNA methylation changes at CpG sites in cord blood are associated with preterm birth risk. CpG-based methylation models demonstrate high predictive accuracy and hold promise for early clinical risk assessment.